BIOTECH CATALYST AI SCANNER — April WK1

Alex

30 Mar 2026 — 22 min read

The biotech sector enters April under significant stress. XBI remains in a pronounced downtrend, and broad market volatility has bled heavily into small-cap names — particularly those approaching binary catalysts. Most featured candidates this week are sitting at or near oversold levels, with eight of ten showing negative 21-day momentum. That kind of synchronized selling usually signals either sector-wide capitulation or a setup for sharp reversals on positive data. Either way, the current environment demands heightened caution: this market is deeply unpredictable, and close monitoring of positions is essential.

April's catalyst calendar is dominated by AACR (April 17–22, San Diego), with a cluster of presentations spanning oncology, immunotherapy, and targeted alpha therapy. Outside of AACR, we're tracking SGO (April 10–13, San Juan), ASCRS (April 10–13, Washington D.C.), AAN (April 18–22, Chicago), and a critical PDUFA decision on April 23. The concentration of events in a single two-week window creates both opportunity and whipsaw risk — expect elevated volatility across the board. Macro headwinds, geopolitical uncertainty, and rate-cut ambiguity continue to weigh on risk appetite, making position sizing and stop discipline more important than usual.

What We're Tracking:

Trading Below Cash: BCYC, ACRV, PLRX
Cash Pressure: GLSI, ONCY
Initial Data: CABA
Multi-Catalyst: ONCY, ADAG, VSTM, KYTX, ACRV, ZYME

FEATURED

#1. LPCN — Lipocine Inc.

THE CATALYST Event: LPCN 1154 (oral brexanolone) — Phase 3 Topline Results in Postpartum Depression Date: Apr 2026 (Est.)
BSI: 8.09/10

LPCN 1154 delivers brexanolone — the same neuroactive steroid behind Sage's IV-only Zulresso — in an oral pill. That means outpatient PPD treatment with rapid onset, no 60-hour hospital infusion required.

The Setup: Sage's Zulresso proved brexanolone works for PPD but chained it to a hospital bed. Zurzuvae (Sage/Biogen) went oral but requires a longer treatment course. Lipocine is betting a shorter oral regimen can carve out the middle ground — convenient enough for broad adoption, fast enough to match the neuroactive steroid's rapid mechanism. The stock has shed 28% in three weeks on zero company-specific news, creating a contrarian entry ahead of topline Phase 3 data.

Science & Edge: LPCN 1154 is chemically identical to allopregnanolone, a positive allosteric modulator of GABA-A receptors that provides rapid PPD relief. Unlike Zulresso's 60-hour continuous hospital infusion or SSRIs that take weeks to work, this oral formulation delivers a 48-hour at-home dosing regimen. Phase 3 enrolled 90 patients with primary endpoint of change from baseline in Hamilton Depression Rating Scale (HAM-D). The DSMB reviewed data from 82 randomized patients and recommended continuing without modification, noting zero severe adverse events. The 505(b)(2) NDA pathway leverages existing brexanolone safety data.

The Edge: Lipocine's 505(b)(2) regulatory path leverages existing brexanolone safety data, potentially shaving years off development vs. a novel compound. Sage already proved the mechanism; Lipocine just needs to prove the delivery. The Risk: A 90-patient Phase 3 is modestly powered. If the effect size comes in smaller than the open-label Phase 2 suggested, the study could miss — and with $24M in cash, there's no second shot without raising capital first.

#2. IPHA — Innate Pharma S.A.

THE CATALYST Event: IPH5201 — (MATISSE) — Phase 2 Oral Presentation at AACR Clinical Trials Plenary Session in Neoadjuvant lung cancer Date: Apr 21, 2026
BSI: 7.76/10

IPH5201 blocks CD39, an enzyme that degrades immunostimulatory ATP in the tumor microenvironment, starving the immune system of activation signals. By forcing ATP accumulation, it flips tumors from immunologically "cold" to "hot." First-in-class mechanism paired with AstraZeneca's durvalumab.

The Setup: Innate just landed a Clinical Trials Plenary Session oral at AACR — the most prestigious presentation format at the conference, reserved for a handful of the most significant clinical datasets each year. That selection alone signals the MATISSE data has substance. The interim readout covers 40 of a planned 70 patients evaluating IPH5201 plus durvalumab plus platinum chemotherapy in neoadjuvant stage II–IIIA NSCLC. Volume has spiked 3.2x recently, suggesting the market has noticed. But Innate's financial reality demands attention: €44.8M in cash as of December 2025 with a going-concern warning, runway only through Q3 2026, and a $75M untapped ATM facility. The AstraZeneca partnership (up to $885M in milestones, $60M received to date) makes positive MATISSE data potentially transformative — it could trigger a Phase III option exercise with 50/50 European profit sharing.

Science & Edge: MATISSE combines IPH5201 with durvalumab and platinum chemotherapy in neoadjuvant NSCLC. CD39 blockade preserves extracellular ATP (preventing its conversion to immunosuppressive adenosine via the CD73 pathway), a mechanism entirely distinct from the PD-1/PD-L1 axis. The dual-checkpoint approach targets both adenosine-mediated immunosuppression and PD-L1, aiming for synergistic immune activation in early-stage disease.

The Edge: An AACR Clinical Trials Plenary oral is a strong external validation signal. If MATISSE confirms that CD39 blockade adds meaningful benefit to checkpoint inhibition in lung cancer, Innate owns a pathway that Roche, Merck, and Bristol Myers haven't cracked — and AstraZeneca is already contractually committed to the development path. The Risk: Innate carries a going-concern warning and negative shareholders' equity (-€21.7M). Even with positive data, the company must secure non-dilutive financing or a pharma partnership to fund operations past Q3 2026 — and the lacutamab Phase 3 (TELLOMAK-3) in CTCL is contingent on exactly that financing materializing. The $75M ATM provides a dilutive backstop.

#3. GLSI — Greenwich LifeSciences Inc.

THE CATALYST Event: GP2 (GLSI-100) — (FLAMINGO-01) — Phase 3 Conference Presentation in HER2 positive breast cancer Date: Apr 17, 2026
FDA Status: FTD
BSI: 7.47/10

GP2 is a 9-amino acid peptide vaccine that trains the immune system to attack HER2-expressing breast cancer cells post-surgery, aiming to prevent recurrence in patients who've already completed trastuzumab-based treatment.

The Setup: Eighty percent reduction in breast cancer recurrence over five years — that's the Phase IIb headline for GP2 in HLA-A*02 patients. No other adjuvant immunotherapy in the HER2 space comes close to that number; trastuzumab and pertuzumab reduce recurrence by 20–50%. Greenwich has shored up its balance sheet via ATM issuance to roughly $12.5M as of January 2026, enough to cover operations through the year at current burn, though financing remains a recurring concern. Important context: the AACR presentations (two posters, April 20–21) focus on preliminary delayed-type hypersensitivity immune response data from the open-label arm of FLAMINGO-01 — this is a biomarker validation readout measuring whether patients' immune systems are recognizing the HER2 peptide, not the final Phase III efficacy unblinding. FDA recently approved commercial GP2 manufacturing (January 2026), and the DSMB recommended expanding enrollment in December 2025. Low float (13.9M shares) means any catalyst moves this stock violently in either direction.

Science & Edge: GLSI-100 demonstrated 80%+ reduction in breast cancer recurrence over 5 years in Phase IIb HLA-A02 patients. The peptide vaccine induces HER2-specific cellular immunity targeting overexpression present in roughly 15–20% of breast cancers — a subset historically associated with more aggressive disease. Phase III interim data from non-HLA-A02 arms shows approximately 70–80% reduction in recurrence rate versus historical controls, suggesting broader applicability beyond the HLA-restricted population.

The Edge: No approved cancer vaccine prevents HER2+ breast cancer recurrence. If Phase III confirms the 80% reduction across HLA genotypes, GLSI-100 would be a first — and Fast Track designation supports an expedited review path that trastuzumab biosimilars can't replicate. The Risk: Phase IIb's HLA-A*02 enrichment may have inflated the effect size. The Phase III primary endpoint requires a hazard ratio of 0.3, an extremely high bar. While the ATM facility provides ongoing access to capital, the company remains heavily dependent on continued share issuance to fund operations — any data disappointment at AACR could impair both the stock price and the ability to raise on favorable terms.

#4. NUVB — Nuvation Bio Inc. Class A

THE CATALYST Event: Taletrectinib — (TRUST-I) (China) — Phase 2 Conference Presentation in ROS1-positive NSCLC Date: Apr 21, 2026
FDA Status: BTD, ODD
BSI: 7.42/10

Taletrectinib (IBTROZI) is a next-generation, brain-penetrant ROS1 inhibitor that already won FDA approval on June 11, 2025. It delivers unprecedented durability — approximately 44-month median duration of response and 46-month median progression-free survival in treatment-naive patients — far outpacing older ROS1 drugs like crizotinib and entrectinib.

The Setup: Nuvation is the rare biotech that's already across the FDA finish line. Taletrectinib is approved in the US, China, and Japan for ROS1+ NSCLC, with EMA review ongoing. Yet the stock has dumped 28% in three weeks, dragged down by broad biotech selling rather than any company-specific problem. The AACR presentation updates long-term TRUST-I/II data — if durability holds beyond the current ~44-month DOR, it reinforces best-in-class positioning against crizotinib (first-gen, poor brain penetration) and entrectinib (broader but less selective). With nearly five years of cash runway, Nuvation can play the long game while competitors scramble for approvals.

Science & Edge: Taletrectinib selectively inhibits ROS1 fusions driving roughly 2% of NSCLC, with strong CNS penetration addressing brain metastases common in ROS1+ patients. TRUST-I/II Phase 2 showed 89% ORR in treatment-naive and 56% in pretreated patients. Updated median duration of response stands at approximately 44 months for treatment-naive patients with median PFS of approximately 46 months, substantially exceeding crizotinib and entrectinib benchmarks.

The Edge: Already FDA-approved with Breakthrough Therapy and Orphan Drug designations. Confirmatory Phase 3 (TRUST-III) is head-to-head against crizotinib, the current standard — if Nuvation wins, it cements global ROS1 dominance across three continents. The Risk: Grade 3/4 ALT elevations hit 13% of patients — hepatotoxicity could limit uptake, particularly in a post-approval setting where physician comfort matters. ROS1+ NSCLC is a rare mutation (~2% of all NSCLC), capping the addressable market regardless of how good the drug is.

#5. SRPT — Sarepta Therapeutics Inc.

THE CATALYST Event: AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen) — NDA Filing Submission in Duchenne muscular dystrophy (DMD) Date: Apr 2026 (Est.)
BSI: 7.24/10

Sarepta's exon-skipping therapies restore partial dystrophin production in DMD patients by allowing the cellular machinery to skip over mutated gene segments. A precision genetic approach with no equivalent in standard DMD care.

The Setup: Two accelerated-approval drugs now seek traditional FDA approval — the regulatory equivalent of converting a provisional license to a permanent one. The ESSENCE Phase 3 trial is the hinge, and it's complicated: numerical improvement (0.06 steps/second decline vs. placebo) but a missed primary endpoint (P=0.309). Sarepta is banking on real-world evidence and post-hoc subgroup analyses to convince FDA. Meanwhile, ELEVIDYS (delandistrogene moxeparvovec), Sarepta's own gene therapy, offers a potentially curative approach but carries higher safety risk. The sNDA filing by end of April sets up a binary regulatory debate that could define DMD treatment for the next decade.

Science & Edge: AMONDYS 45 and VYONDYS 53 employ antisense oligonucleotide exon-skipping to restore dystrophin in mutation-specific patient populations. Accelerated approval was based on dystrophin protein increases. ESSENCE showed numerical improvement but missed statistical significance at 96 weeks; post-hoc analyses suggest clinical meaningfulness in predicted-decline subgroups with favorable safety profiles.

The Edge: Sarepta has years of accumulated real-world safety and efficacy data across thousands of DMD patients — evidence that no competitor in the exon-skipping space can match. FDA has signaled openness to real-world data for conversion decisions. The Risk: ESSENCE missed its primary endpoint. Period. FDA has never converted an accelerated approval based primarily on a failed confirmatory trial plus real-world evidence. If the agency holds the statistical line, Sarepta loses not just the conversion but credibility across its entire exon-skipping franchise.

#6. OKYO — OKYO Pharma Limited

THE CATALYST Event: Urcosimod (OK-101) — Phase 2a Conference Presentation in Neuropathic corneal pain (NCP) Date: Apr 11, 2026
FDA Status: FTD
BSI: 6.98/10

Urcosimod is a lipid-conjugated chemerin peptide that activates ChemR23 receptors on eye immune cells and neurons, reducing both inflammation and neuropathic pain in the cornea. There are zero FDA-approved treatments for NCP today.

The Setup: No approved drug. No direct competitor in the clinic. OKYO owns the first IND ever filed for neuropathic corneal pain — a condition currently managed with off-label drops that weren't designed for the underlying problem. The stock sits at oversold levels (RSI 29.5) with director share purchases on record, suggesting insider confidence the market hasn't priced. The ASCRS presentation on April 11 precedes a larger ARVO showing in May. But the cash situation is dire: $6.3M won't fund the planned 150-patient Phase 2b/3 without a raise.

Science & Edge: Phase 2a data (n=12) showed meaningful VAS pain reduction and quality-of-life gains — patients reported a mean change of -4.5 in enjoying life/relationships versus 0 for placebo. Urcosimod builds on prior dry eye disease Phase 2 success, targeting ChemR23 to curb inflammation via a distinct mechanism from any existing ophthalmic therapy.

The Edge: First-in-class and first-in-disease. Fast Track designation in a space with zero approved therapies gives OKYO regulatory leverage that larger competitors in adjacent ophthalmology indications don't have for NCP specifically. The Risk: Twelve patients. That's the entire efficacy dataset. Phase 2a was exploratory, and the jump to a 150-patient Phase 2b/3 is enormous — both scientifically and financially. With less than a month of runway, any financing will dilute shareholders before data can mature.

#7. BCYC — Bicycle Therapeutics plc

THE CATALYST Event: BT5528 and OPDIVO (nivolumab) — Phase 1/2 Conference Presentation in Solid tumors Date: Apr 19, 2026
BSI: 6.96/10

Bicycle develops bicyclic peptide-drug conjugates — molecules small enough to penetrate solid tumors that conventional antibody-drug conjugates can't reach. BT5528 targets EphA2, a receptor largely untouched in oncology because antibodies struggle to access it effectively.

The Setup: The market is paying $300M for a company sitting on $628M in cash. That's not a typo — Bicycle trades at a roughly $328M discount to its own bank account, with runway now extending into 2030 after a strategic restructuring. The 30% workforce reduction spooked investors, but it also freed capital to focus entirely on BT5528. Oversold at RSI 27 with volume spiking 1.9x, someone is accumulating into this dislocation. AACR data on April 19 tests whether the EphA2 combination with nivolumab can build on the 43% ORR seen in EphA2-positive patients at ESMO 2024 — versus 20% in EphA2-negative, confirming target-dependent activity.

Science & Edge: BT5528 combines EphA2 targeting with nivolumab across solid tumors. Prior data showed 43% ORR in EphA2-positive patients versus 20% in EphA2-negative — a clear signal of target-dependent activity. The bicyclic peptide architecture enables pharmacokinetic and tissue penetration advantages over conventional monoclonal antibody conjugates.

The Edge: EphA2 is a near-virgin oncology target — most competitors pursue validated antigens like Nectin-4 and HER2. Bicycle's platform can reach tumor sites that standard ADCs simply can't access, and the $628M cash position eliminates financing risk well through Phase 2 completion and into 2030. The Risk: Zelenectide, Bicycle's other lead program, was deprioritized despite a 58–62% ORR after FDA regulatory feedback forced a trial redesign. That precedent raises questions about whether the agency sees platform-level concerns with Bicycle's conjugate approach, not just zelenectide-specific issues.

#8. ONCY — Oncolytics Biotech Inc.

THE CATALYST Event: Pelareorep and TECENTRIQ (atezolizumab) — (AWARE-1) — Phase 1 Conference Presentation in Breast cancer Date: Apr 17, 2026 Additional catalysts: 1 more within 90 days
BSI: 6.89/10

Pelareorep is an oncolytic virus that converts immunologically "cold" tumors into "hot" ones by triggering interferon production, dendritic cell activation, and cytotoxic T-cell priming — making cancer visible to the immune system where checkpoint inhibitors alone fail.

The Setup: RSI at 21.6 — the most oversold name on this week's list. Two AACR presentations in the same week: AWARE-1 breast cancer data and GOBLET colorectal/anal cancer data. This is the definition of binary pressure. Cash has been declining steadily (from ~$15.9M at end of 2024 to an estimated ~$10M entering Q2 2026), and while runway extends into the coming months rather than weeks, the financing picture remains urgent. The GOBLET program previously reported 29% ORR and 62% ORR in pancreatic cancer with PFS of 7.5 vs. 5.6 months over standard care. If AWARE-1 confirms the immune-priming mechanism in breast cancer, Oncolytics has a platform story. If not, the company faces near-term dilution with minimal cash buffer.

Science & Edge: Pelareorep combined with atezolizumab in the AWARE-1 window-of-opportunity study induces coordinated immune activation: cytotoxic T cells, dendritic cells, and B cells forming tertiary lymphoid structures in tumor biopsies. This goes beyond simple checkpoint blockade — pelareorep primes systemic immunity and stimulates RAS-specific T-cell responses.

The Edge: Two independent datasets (breast and GI cancers) testing the same immune-priming mechanism at the same conference. If both confirm tertiary lymphoid structure formation, pelareorep becomes a potential backbone combination agent — a position no other oncolytic virus has reached in solid tumors. The Risk: Limited cash and a near-term financing need remain the dominant concern. Even positive AACR data requires partnership or financing to continue operations beyond mid-2026. Phase 1 window-of-opportunity studies generate biomarker signals, not registrational evidence — the path from here to an approvable Phase 3 is long and expensive for a company running on a short runway.

#9. CATX — Perspective Therapeutics

THE CATALYST Event: [212Pb]VMT-α-NET — Phase 1 Conference Presentation in Neuroendocrine tumors (NETs) Date: Apr 20, 2026
BSI: 6.88/10

VMT-α-NET delivers lead-212 alpha radiation directly to somatostatin receptor-expressing neuroendocrine tumors. Alpha particles pack higher energy into a shorter range than the beta-emitters used by Novartis's Lutathera — potentially killing more tumor cells while sparing surrounding tissue.

The Setup: The radiopharmaceutical space is red-hot after Novartis acquired Advanced Accelerator Applications and Bristol Myers bought RayzeBio. CATX sits in that same targeted radionuclide therapy lane but with a differentiated alpha-emitter approach and a proprietary decentralized manufacturing network. The stock has been crushed alongside the broader biotech selloff — down 25% in three weeks, oversold at RSI 26.7, with volume drying up to 0.2x normal. A post-raise cash position of $295M funds operations into late 2027. AACR on April 20 updates Phase 1 cohort 1-3 data following the 39% ORR and clean safety profile (no DLTs across 56 patients) reported at ASCO-GI.

Science & Edge: VMT-α-NET targets SSTR2 on neuroendocrine tumors via a theranostic alpha-emitter platform enabling imaging-guided therapy. Phase 1 showed 39% ORR in Cohort 2 (5.0 mCi) with durable responses across 56 patients and no dose-limiting toxicities — regardless of SSTR2 expression levels. Alpha particles provide higher linear energy transfer and shorter path length than beta-emitters like Lutathera, potentially improving tumor kill while reducing bone marrow toxicity.

The Edge: Perspective's decentralized finishing network solves the manufacturing bottleneck that plagues centralized radiopharmaceutical producers. Combined with a Bristol Myers collaboration on VMT01 for melanoma, the platform has multi-indication reach that single-asset radioligand companies lack. The Risk: Phase 1 dose-escalation data in 56 patients, no matter how clean, doesn't prove efficacy at registrational standards. Alpha radiotherapy is novel enough that FDA may require bridging studies before advancing to pivotal trials. R&D spend doubled to $84M in 2025, and even with $295M in cash, that burn rate compresses the timeline.

#10. EVAX — Evaxion A/S

THE CATALYST Event: EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab) — Phase 2b Conference Presentation in Metastatic Melanoma Date: Apr 22, 2026
FDA Status: FTD
BSI: 6.61/10

EVX-01 is an AI-designed personalized neoantigen vaccine. Each dose is custom-built from a patient's own tumor mutations, training T cells to recognize and kill cancer cells that standard checkpoint inhibitors miss.

The Setup: The personalized cancer vaccine race has a frontrunner — Moderna's mRNA-4157 (V940) with Merck in Phase 3. Evaxion is the small-cap dark horse running a different playbook: AI-driven antigen selection rather than mRNA delivery. At $29M market cap with a micro float (8.3M shares), this is a name that moves fast on any catalyst. The stock has shown rare positive momentum (+11.4%) while most biotech names bleed, suggesting pre-AACR positioning. Cash runway extends into the second half of 2027, providing enough time to generate mature Phase 2b data and pursue partnerships. The April 22 presentation covers preclinical durable de novo T-cell responses, with three-year Phase 2 survival data coming in the second half of 2026.

Science & Edge: EVX-01 uses an AI-immunology platform to identify neoantigens for bespoke vaccines, stimulating durable de novo T-cell responses in advanced melanoma patients on PD-1 inhibitors. The AACR data will highlight biomarker and immunogenicity results from Phase 2b. Unlike standard PD-1 monotherapy, EVX-01 adds personalized tumor-specific immunity to target non-responders.

The Edge: Evaxion's AI platform designs vaccines in days rather than the months required by manual neoantigen selection — a manufacturing speed advantage that Moderna and BioNTech's approaches don't inherently solve. Fast Track designation adds regulatory urgency. The Risk: This AACR presentation covers preclinical and biomarker data, not registrational efficacy. Moderna/Merck's V940 is years ahead in development with orders-of-magnitude more resources. While the cash runway is more comfortable than many names on this list, a $29M company still needs a partnership to fund a Phase 3 program — and that partnership may not materialize at favorable terms.

WATCHLIST

#11. ADAG — Adagene Inc. [Immuno-Oncology]

Price: $3.77 | Cap: $177.7M | Cash: $85.2M | RSI: 60.7 | Momentum: 27.4% ADG126 with atezolizumab and bevacizumab (triple combo) — (Morpheus Liver) — Phase 1/2 Conference Presentation in Advanced hepatocellular carcinoma (Apr 20, 2026) Additional catalysts: 1 more within 90 days BSI: 6.57/10

The Intel: ADG126 (muzastotug) is a masked anti-CTLA-4 antibody designed to activate in the tumor microenvironment while limiting systemic toxicity — the same toxicity problem that held back Bristol Myers's ipilimumab in liver cancer. AstraZeneca's durvalumab plus bevacizumab is already the standard of care for HCC, so the question is whether adding a conditionally-active CTLA-4 layer meaningfully improves outcomes. Two AACR presentations (Morpheus Liver + KEYNOTE-C98 solid tumor data) plus strong recent momentum (+27.4%) make this a name to watch, though Phase 1/2 cohort sizes typically limit the signal.

#12. VSTM — Verastem Inc. [Oncology]

Price: $5.04 | Cap: $442.7M | Cash: $175.4M | RSI: 29.7 | Momentum: -11.9% Avutometinib in Combination with Defactinib — (RAMP 201) — Phase 2 Conference Presentation in Low-Grade Serous Ovarian Cancer (Apr 10, 2026) Additional catalysts: 1 more within 90 days BSI: 6.56/10

The Intel: Verastem already landed FDA approval for avutometinib plus defactinib in KRAS-mutant recurrent LGSOC — the first breakthrough in a disease with no prior targeted options. The SGO presentation on April 10 updates RAMP 201J data (38% ORR in 16 patients) while a separate AACR abstract covers VS-7375, a KRAS G12D inhibitor in early-stage solid tumors. Oversold at RSI 29.7, the stock's weakness appears disconnected from the company's execution. MEK/FAK combination continues to show durable activity in KRAS-driven tumors, competing in a space where Mirati (now BMS) and Amgen's sotorasib dominate the conversation.

#13. KYTX — Kyverna Therapeutics Inc. [Autoimmune]

Price: $7.80 | Cap: $471.4M | Cash: $246.1M | RSI: 41.8 | Momentum: -5.0% Miv-cel (mivocabtagene autoleucel, KYV-101) — (KYSA-6) — Phase 2 Interim Data in Myasthenia gravis (Apr 20, 2026) FDA Status: FTD, ODD, RMAT Additional catalysts: 1 more within 90 days BSI: 6.55/10

The Intel: Kyverna's CAR-T approach to autoimmune disease is one of the most watched spaces in biotech. Miv-cel achieved 100% clinically meaningful responses in MG at 24 weeks (MG-ADL and QMG co-primary endpoints) in Phase 2 interim data. AAN brings a packed schedule: updated MG data on April 20, plus a late-breaking oral presentation on April 21 covering the primary analysis of the KYSA-8 registrational Phase 2 in stiff-person syndrome — where topline data already showed statistically significant clinical benefit with no high-grade cytokine release syndrome. The SPS BLA submission is on track for H1 2026, targeting a commercial launch by year-end. Cabaletta (CABA, #15) is the closest competitor in autoimmune CAR-T, and both present the same week. Triple FDA designations (Fast Track, Orphan, RMAT) reflect regulatory enthusiasm.

#14. MIRA — MIRA Pharmaceuticals Inc. [Neuroscience]

Price: $1.03 | Cap: $43.1M | Cash: $5.3M | RSI: 42.3 | Momentum: -18.9% Ketamir-2 — Phase 1 Conference Presentation in Healthy volunteers, neuropathic pain (Apr 17, 2026) BSI: 6.53/10

The Intel: Ketamir-2 is an oral ketamine analog with a twist: non-controlled substance status per DEA, better oral bioavailability, and a cleaner side effect profile than IV ketamine. Phase 1 dosing completed in March 2026 with clean safety across all dose levels. However, our scoring flagged catalyst materiality and trial design as concerns — this is Phase 1 healthy volunteer data at AACR, not a pivotal efficacy readout. The neuropathic pain market is large but crowded with generics. Phase 2a is planned but unfunded at current cash levels.

#15. CABA — Cabaletta Bio Inc. [Autoimmune]

Price: $2.68 | Cap: $298.3M | Cash: ~$163.6M | RSI: 29.1 | Momentum: -19.3% Resecabtagene autoleucel (rese-cel) — (RESET-MG) — Phase 1/2 Initial Data in Generalized myasthenia gravis (Apr 20, 2026) BSI: 6.50/10

The Intel: Cabaletta is Kyverna's direct competitor in autoimmune CAR-T, using a fully human 4-1BB CD19-CAR T approach to deplete pathogenic B cells in MG. Both present at AAN the same week, making April 20 a head-to-head comparison day for the autoimmune CAR-T thesis. Rese-cel's initial RESET-MG data will be the first clinical look at Cabaletta's construct in MG specifically. Oversold at RSI 29.1, the stock has pulled back despite a stronger balance sheet than the market appreciates — $133.6M at year-end 2025 plus $30M raised in Q1 2026 via ATM and warrant exercises, with management guiding runway into Q4 2026. A critical differentiator: Cabaletta is exploring cohorts without lymphodepleting preconditioning, which could enable outpatient CAR-T administration — a potential access advantage over Kyverna's standard lymphodepletion approach.

#16. ACRV — Acrivon Therapeutics Inc. [Oncology]

Price: $1.33 | Cap: $51.5M | Cash: $118.6M | RSI: 30.4 | Momentum: -11.9% ACR-2316 — Phase 1 Conference Presentation in Solid Tumors (Apr 20, 2026) Additional catalysts: 1 more within 90 days BSI: 6.23/10

The Intel: Another negative EV situation — $118.6M in cash and investments for a company trading at $51.5M. ACR-2316 is a dual WEE1/PKMYT1 inhibitor with Phase 1 data showing tumor shrinkage and partial responses across multiple solid tumors. AACR brings two presentations: ACR-2316 early data plus ACR-368 Phase 2b ovarian cancer results (39% ORR in biomarker-positive, 67% in serous subtype). The biomarker-driven approach competes conceptually with AstraZeneca's adavosertib (which was discontinued) — if Acrivon can succeed where AZ failed, the WEE1 space reopens.

#17. TGTX — TG Therapeutics Inc. [Neurology]

Price: $31.75 | Cap: $5.07B | Cash: $361.4M | RSI: 61.0 | Momentum: 5.5% BRIUMVI (ublituximab-xiiy) — (ENHANCE) — Phase 3 Conference Presentation in Relapsing MS (Apr 21, 2026) BSI: 6.17/10

The Intel: BRIUMVI is already approved and generating revenue in relapsing MS, competing against Roche's Ocrevus and Novartis's Kesimpta. The ENHANCE trial explores 30-minute infusions (vs. standard longer infusions), addressing a key convenience barrier. Phase 3 enrollment is complete, with pivotal topline data expected mid-2026. At $5B market cap, this is the largest name on the list — the AAN presentation is a commercial catalyst rather than a survival question, and BRIUMVI's glycoengineered anti-CD20 approach continues to show competitive efficacy with reduced treatment burden.

#18. GRCE — Grace Therapeutics Inc. [Rare Disease]

Price: $4.67 | Cap: $62.7M | Cash: $16.5M | RSI: 84.3 | Momentum: 8.9% GTX-104 — (STRIVE-ON) — PDUFA Regulatory Decision in Subarachnoid hemorrhage (Apr 23, 2026) FDA Status: ODD BSI: 6.11/10

The Intel: The hardest binary on this week's list. GTX-104 is an IV nimodipine formulation for subarachnoid hemorrhage — the oral version has been standard of care for decades but has absorption and dosing consistency issues. Orphan Drug Designation and a PDUFA date of April 23 make this a pure regulatory coin flip. RSI at 84.3 signals the stock has already priced in significant optimism. If FDA approves, Grace fills an unmet reformulation need in a defined market. If not, the overbought position unwinds fast.

#19. PLRX — Pliant Therapeutics Inc. [Oncology / Fibrosis]

Price: $1.17 | Cap: $72.4M | Cash: $173.4M | RSI: 38.5 | Momentum: -10.0% PLN-101095 — Phase 1 Conference Presentation in Solid Tumors (Apr 18, 2026) BSI: 6.02/10

The Intel: Pliant trades at negative enterprise value — $173M cash backing a $72M market cap — after its lead fibrosis program disappointed. PLN-101095 pivots to oncology, blocking αvβ8/αvβ1 integrins to counter TGF-β-driven immunotherapy resistance. The AACR presentation is early Phase 1 data with interim results not expected until 2027. Our scoring flagged catalyst materiality and trial design as concerns — this is an early-stage poster at a conference, not a pivotal readout. The value thesis here is the cash, not the near-term catalyst.

#20. ZYME — Zymeworks Inc. [Oncology]

Price: $24.18 | Cap: $1.78B | Cash: $468.7M | RSI: 49.6 | Momentum: 3.8% Zanidatamab — (NeoZanHER) — Phase 2 Conference Presentation in HER2 positive Breast Cancer (Apr 18, 2026) Additional catalysts: 3 more within 90 days BSI: 6.01/10

The Intel: Zymeworks is the multi-catalyst king this week — four events within 90 days including NeoZanHER breast cancer data, DiscovHER pan-tumor data, ZW191-101 Phase 1 results (44% ORR at AACR-NCI-EORTC), and zanidatamab plus evorpacept at ESMO Breast Cancer in May. Zanidatamab (Ziihera) is a bispecific HER2 antibody competing against Daiichi Sankyo's T-DXd and Roche's established HER2 franchise. With 11+ years of runway and royalty-driven economics, this is a fortress-style position. The risk is dilution of focus across too many readouts, none of which may individually move the needle for a $1.78B company.

The Strategist's Take

This week's scanner paints a picture of a sector under duress but loaded with near-term catalysts. Eight of ten featured names show negative 21-day momentum, and five sit below RSI 30. That's unusual even for biotech — and it creates a setup where positive data at AACR could trigger outsized moves simply because expectations have been beaten down so aggressively. But let's not sugarcoat it: this market environment is treacherous and deeply unpredictable. Tariff whiplash, rate uncertainty, and sector rotation out of speculative names mean that even good data may not save a stock if macro conditions deteriorate further. Close, active monitoring of every position is non-negotiable right now.

The AACR cluster (April 17–22) is the main event. IPHA (#2, BSI 7.76) earned an oral presentation at the Clinical Trials Plenary Session — an exceptionally rare distinction that suggests the MATISSE data is meaningful, though the company's going-concern warning and limited runway into Q3 2026 add urgency. GLSI (#3, BSI 7.47) carries the strongest Phase IIb precedent — an 80% recurrence reduction — but the AACR posters are biomarker immune-response data, not the Phase III efficacy unblinding; manage expectations accordingly. BCYC (#7, BSI 6.96) offers the cleanest deep-value setup: trading over $300M below cash with early data showing target-dependent activity in a space no one else is playing. ONCY (#8, BSI 6.89) remains a high-conviction binary — two AACR presentations and limited cash reserves, though not the "zero cash" situation the raw scanner data initially suggested. The negative EV names (BCYC, ACRV, PLRX) collectively represent a structural anomaly worth monitoring, though remember that the market often has reasons for pricing companies below cash that aren't immediately visible.

On the watchlist, the KYTX (#13) vs. CABA (#15) showdown at AAN deserves special attention — both present autoimmune CAR-T data in myasthenia gravis during the same week, with Kyverna also delivering a late-breaking oral on its SPS registrational data. CABA's balance sheet is stronger than the raw scanner data suggested (~$164M pro forma), and its exploration of lymphodepletion-free cohorts could be a long-term access differentiator. GRCE (#18) is the purest binary with its April 23 PDUFA, but RSI 84.3 suggests the market has already placed its bet. Our scoring flagged MIRA (#14) on catalyst materiality and trial design, and PLRX (#19) on the same dimensions — approach both with extra caution, as conference posters in early-phase programs rarely generate tradeable catalysts.

A note on data accuracy: Several cash figures and runway estimates in this week's scanner required correction after cross-referencing against the latest SEC filings and corporate disclosures. Automated financial data extraction remains an imperfect process, particularly for companies reporting in non-USD currencies or with complex partnership structures. We've updated all figures to reflect the most recent verified data available. As always, confirm financials against primary filings before making investment decisions.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings. Catalyst dates are estimates based on company guidance and subject to change.

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.